Cabozantinib, which is a MET inhibitor, inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in liver cancer progression [52]. This evidence concerns the gene FLT1 and liver cancer.